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Background: Intramuscular injections of vitamin A decrease the risk of broncho-pulmonary 
dysplasia. Admixture of vitamin A with surfactant as a lipophilic vehicle might be a less inva-
sive modality.
Aim: Test physical properties of surfactant + vitamin A.
Methods: Miscibility and surface activity were tested in surfactant supplemented with retinyl-
acetate, -palmitate, 13-cis-, or all-trans-retinoic acid.
Results: Retinol acetate (5000 IU/mL) demonstrated miscibility with surfactant when premixing 
with ethanol. Its surface activity was 40% lower compared to surfactant alone.
Conclusion: These ﬁ  ndings warrant preclinical studies to test whether administration of 
vitamin A in subjects requiring surfactant is associated with beneﬁ  cial functional properties.
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Introduction
Broncho-pulmonary dysplasia (BPD) is characterized by decreased alveolarization, 
a localized inﬂ  ammatory response, pulmonary infections, and impaired pulmonary 
vascular growth (D’Angio and Maniscalco 2004; Stenmark et al 2005). BPD is an 
important cause of death and long-term disability among extremely low birth weight 
(ELBW) infants (Smith et al 2004). Conventional treatments for BPD include various 
modalities of ventilation, high dose systemic corticosteroids, diuretics, antiinﬂ  amma-
tory agents, antiinfective agents, and antioxidants (D’Angio and Maniscalco 2004) 
such as vitamin A (Ambalavanan et al 2004).
Vitamin A is the generic name for a group of fat-soluble compounds which have 
the biological activity of the primary alcohol, retinol. In vitro and in physiologic 
animal models, it has been demonstrated that vitamin A is involved in the regulation 
and promotion of growth and differentiation of many cells (Ozer et al 2005). In the 
lung it promotes alveolar repair, protects against hyperoxia mediated cell-cycle arrest, 
stimulates surfactant synthesis, and improves pulmonary vascularization (Maden 
et al 2004; Snyder et al 2005). Since retinol accretion occurs during late gestation, 
premature infants are more prone to vitamin A deﬁ  ciency (Hustead et al 1984; Shenai 
et al 1985).
Evidence from randomized trials supports parenteral vitamin A supplementation 
with reported reduction in death or oxygen requirement (Darlow and Graham 2002) 
in premature infants ventilated for respiratory distress syndrome (RDS). However, 
Vitamin A supplementation in ELBW infants is not routinely practiced, perhaps, 
because the current mode of administration through multiple intramuscular injections 
is considered invasive (Ambalavanan et al 2004), which accounts for the search for 
alternate modalities of administration of this lipophilic antioxidant vitamin.
Vitamin A administration is challenging as it may have unwanted effects like 
increased intracranial pressure, liver toxicity, or drug interactions at high doses (Fran-
cisko et al 1993; Ambalavan et al 2003). Oral supplementation with vitamin A may 
not be efﬁ  cacious (Wardle et al 2001). Intravenous administration of vitamin A in total Drug Design, Development and Therapy 2008:2 146
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parenteral nutrition is not satisfactory because of photo degra-
dation (Allwood and Martin 2000) and signiﬁ  cant adsorption 
to the tubing (Haas et al 2002). Contrary to the antioxidant 
vitamins C and E that increase in lungs with infused concen-
trations, pulmonary levels of vitamin A remain undetectable 
(Lavoie et al 2007). Vitamin A compounds administered into 
the lungs via the upper airway have been shown to be biologi-
cally active in humans (Biesalski et al 1999; Kohlhauf l et al 
2002), which suggests that this may be a route of administra-
tion worth investigating in premature infants.
A majority of premature ELBW infants with RDS receive 
exogenous surfactant which has surface tension properties 
that contribute to improve the ventilation perfusion ratio of 
the immature lungs. The high phospholipid and apoprotein 
content of surfactant account for its lipophilic properties. It 
was deemed of therapeutic interest to test whether vitamin A 
can be co-administered with surfactant as a lipophilic vehicle 
to provide an alternate, less invasive, approach to providing 
this antioxidant vitamin in premature infants who require 
surfactant replacement therapy. The objective of this study 
was to determine in vitro the effect of the admixture of vita-
min A with a clinically relevant surfactant preparation on 
miscibility and surface tension properties.
Methods
We tested the miscibility/solubility and surface activity of 
bovine surfactant (BLES Biochemicals Inc., London, On, 
Canada) ± alcohol (100% denatured, Sandoz, Boucherville, 
QC, Canada) ± emulsiﬁ  ers (tween 80: polyoxyethylenesor-
bitan monooleate from Sigma-Aldrich, Canada; tyloxapol: 
4-(1,1,3,3-tetramethylbutyl) phenolpolymer with formalde-
hyde and oxirane from Sigma-Aldrich, Canada) supplemented 
with 5000 or 50000 IU/mL of the following vitamin A deriva-
tives: -retinly acetate, -retinyl palmitate, -13-cis retinoic acid, 
-all-trans retinoic acid (ATRA) from Sigma-Aldrich, Canada. 
The bovine surfactant was provided graciously for the study 
by BLES Biochemicals Inc.
To prepare the “surfactant + vitamin A” solution, 5000 
or 50000 IU of vitamin A derivatives were dissolved directly 
and vortexed into 1 mL BLES. To prepare the “surfactant + 
vitamin A + alcohol” preparation, a stock solution of 50000 
IU/mL vitamin A dissolved in alcohol was vortexed with 
1 mL BLES. The 5000 IU/mL vitamin A solution was 
obtained by dilution of the 50000 IU/mL before mixing 
with 1 mL BLES. The “surfactant + vitamin A + emulsi-
ﬁ  ers” preparation was the same as above, apart from using 
tyloxapol (25 mg) or tween 80 instead of alcohol. Tyloxapol 
is a strong detergent that contributes to the dispersion of 
dipalmitoyl phosphatidylcholine in the artiﬁ  cal lung surfac-
tant Exosurf (Burroughs Welcome); whereas tween 80 is a 
common emulsiﬁ  er used in laboratories to solubilize hydro- 
and lipophilic compounds.
Miscibility/solubility was determined at room tempera-
ture and at 37 °C immediately upon mixing the preparation 
and 24 h thereafter by testing visually for macroscopic 
appearance and microscopically using light and ﬂ  uorescence 
for precipitation (Wong et al 2006). Miscibility relates to two 
solutions. Solubility relates to a solution and solids. Mac-
roscopic evaluation (Eggert et al 1982) was performed in a 
plastic test tube after vigorous agitation prior to visual inspec-
tion to determine the presence of opalescence, separation of 
solutions, gross precipitation or crystallization using a strong 
light and a dark background. Preparations not showing the 
above physical signs were considered macroscopically mis-
cible. Using a light microscope at standard magniﬁ  cation (10 
and 100×), evidence of precipitation and crystallization was 
sought in all preparations, while separation of solutions and/
or denaturation of BLES were observed using a ﬂ  uorescent 
microscope. Three determinations were performed for each 
preparation. The technique was validated by verifying that the 
limit of precipitation detected microscopically did not vary 
over multiple samples of the same vitamin A solution.
Surface activity was measured for the vitamin A deriva-
tives exhibiting miscibility in surfactant. Immediately after 
mixing the “surfactant + vitamin A + ethanol” preparation, 
surface activity was measured using a pulsating bubble sur-
factometer (PBS, General Transco Inc., Largo, FL, USA) 
as described by Enhorning (1977). The mixture of 138 μL 
of the preparation diluted in 1362 μL of diluent (240 μL 
absolute ethanol in 260 μL puriﬁ  ed water) was kept at 37 °C 
for 90 minutes prior to determination of surface tension. 
The preparation was then loaded and allowed to equilibrate 
for three minutes in the small volume chamber of the PBS, 
which communicates with ambient air through a chimney. The 
motion of a piston of the PBS produces a negative pressure in 
the chamber until a bubble is formed at the air–liquid interface 
in the chimney. As the bubble is subjected to 20 pulsations 
per minute for 2 ½ minutes, the surface tension is recorded. 
Under optimal conditions a surfactant will induce, after a 
few pulsations, the surface tension to diminish to zero during 
expiration. During each pulsation the bubble formed at the 
surface of the air/surfactant interface will oscillate between 
a maximal surface tension when the bubble has the smallest 
size at baseline, and a minimal surface tension with the larger 
bubble size (Enhorning 2001). Three runs were performed per 
sample. A BLES reference sample was run as control and the Drug Design, Development and Therapy 2008:2 147
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synthetic surfactant Exosurf was run as a further source of 
comparison. Standard descriptive statistics are used.
Results
Partial miscibility/solubility with BLES was achieved for 
retinyl palmitate, ATRA, and 13-cis retinoic acid (Table 1). 
Retinyl acetate demonstrated better miscibility in vitro. The 
miscibility of surfactant + retinyl acetate was improved by 
premixing vitamin A with ethanol. Miscibility/solubility 
deteriorated after 24 h storage at room temperature. Overall, 
miscibility was marginally better with alcohol than with 
emulsiﬁ  ers (tween 80 and tyloxapol). At 37 °C miscibility/
solubility was not improved.
Surface activity was measured to test the effect of vitamin 
A supplementation on physical properties of surfactant. 
As shown is Figure 1, BLES alone was associated after 
25 pulsations with a minimum surface tension of 0, in 2 out of 
3 runs (mean ± SD : 2 ± 2 nN/m). Under the same conditions 
the artiﬁ  cial surfactant Exosurf alone exhibited an average 
minimum surface tension of 29 ± 1 nN/m. After 25 pulsations 
the average minimum surface tension of   “BLES + retinyl 
acetate + alcohol” preparation was 13 ± 4 nN/m for the 
5000 IU/mL preparation (Figure 2) and 15 ± 1 nN/m for the 
50000 IU/mL preparation.
Discussion
The intratracheal route of administration is widely used for 
drugs like epinephrine, atropine sulfate, lidocaine hydrochlo-
ride, or naloxone hydrochloride in emergency situations. This 
route is also used for the delivery of steroids as well as β-2 
agonist in asthma and antibiotics in cystic ﬁ  brosis. The poten-
tial advantage of administering metabolites of vitamin A in 
the lungs is to achieve local bioavailability with decreased 
systemic side effects.
Inhaled forms of retinyl palmitate have been used 
successfully in humans for treatment of respiratory epi-
thelium metaplasia (Kohlhauf l et al 2002), with improved 
blood levels of vitamin A as well as retinol binding protein 
(Biesalski et al 1999). The biologically active metabolite 
13-cis retinoic acid was shown to be effective in inhaled 
form for the prevention of lung cancer in animal studies, 
without causing liver toxicity (Dahl et al 2000). An inhaled 
aerosolized preparation of ATRA, which is the end product 
of vitamin A metabolism that activates receptors, has been 
used in animals for targeted pulmonary delivery (Brooks 
et al 2000). In addition, retinyl acetate is a metabolically 
inert retinyl ester, which we speculate would lead to 
elevated cellular concentrations of vitamin A, without 
affecting metabolic regulatory steps. However, to our 
Table 1 Miscibility/solubility of vitamin A derivatives in bovine surfactant
Retinyl acetate
(IU/mL)
Retinyl Palmitate 
(IU/mL)
ATRA
(mg/mL)
13-cis Retinoid
Acid (mg/mL)
5000 50000 5000 50000 0.2 0.4 0.4 1
Surfactant 
  +
Vitamin A
Immediate Macro −− ±± − − − −
Micro −− −− − − − −
Temp Macro − NA ±± ± ± ± ±
Micro − NA ±± − − − −
Surfactant 
  +
Vitamin A 
  +  
Alcohol
Immediate Macro ++ ±± ± ± ± ±
Micro ++ −− − − ± ±
Temp Macro ++ ±± NA NA ±±
Micro ++ −− NA NA −−
Surfactant 
  +
Vitamin A 
  +
Emulsiﬁ  ers
Immediate Macro NA NA −− ± ± ± ±
Micro NA NA −− − − − −
Temp
 
Macro NA NA −− NA NA NA NA
Micro NA NA −− NA NA NA NA
Notes:
alcohol  ethyl alcohol USP 100% v/v  macro  visually
emulsiﬁ  er  Tyloxapol,   Tween 80® micro  microscopically:  light,  ﬂ  uorescence
immediate  at room temperature upon mixing  + good  miscibility
temp 37  °C  ±  fair miscibility, partial solubility 
NA  data not available  −  not miscible, not dissolved, precipitation, denaturation of BLESDrug Design, Development and Therapy 2008:2 148
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Figure 2 Surface tension properties of the mixture surfactant + retinly acetate + alcohol. Maximum (max) and minimum (min) surface tension (nN/m) as determined by 
pulsating bubble meter in three runs as the bubble formed at the surface of the air /surfactant admixture interface is subject to 20 pulsations per minute for 2 ½ minutes. 
After 25 pulsations the surface tension reaches a minimum of 13 ± 4 nN/m.
0
5
10
15
20
25
30
35
40
45
51
Pulsation Number
S
u
r
f
a
c
e
 
T
e
n
s
i
o
n
 
(
n
N
/
m
 
)
Run 1 min
Run 2 min
Run 3 min
Run 1 max
Run 2 max
Run 3 max
11 21 31 1 41
Figure 1 Surface tension properties of surfactant (BLES®). Maximum (max) and minimum (min) surface tension (nN/m) as determined by pulsating bubble meter in three 
runs as the bubble formed at the surface of the air/surfactant interface is subject to 20 pulsations per minute for 2 ½ minutes.   After 25 pulsations the surface tension reaches 
a minimum of 2 ± 2 nN/m.Drug Design, Development and Therapy 2008:2 149
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knowledge its administration via the lungs has not been 
used in humans.
This is the ﬁ  rst study evaluating the use of exogenous 
surfactant as a vehicle for intra-tracheal administration of 
vitamin A. The results indicate that the retinyl acetate admix-
ture was associated with the better miscibility/solubility in 
surfactant. Our surface activity values for both BLES and 
Exosurf surfactants are similar to those previously reported 
for commercial surfactants from bovine lung extracts or 
synthetic surfactants (Bernhard et al 2000). We found that 
the surface activity of the retinyl acetate admixture was better 
than artiﬁ  cial surfactant, but did not achieve values measured 
with bovine surfactant alone. However, the signiﬁ  cance of 
these values needs to be considered with caution as physical 
properties are not a reliable predictor of clinical outcome. 
The artiﬁ  cial surfactant Exosurf was shown to be associated 
with beneﬁ  cial effects on survival of preterm infants with 
RDS (McMillan et al 1995) in spite of poor in vitro surface 
tension properties (Bernhard et al 2000). Although the 
admixture containing 13-cis retinoic acid exhibited surface 
tension properties that were similar to bovine surfactant 
alone, its partial miscibility/solubility would be a problem 
in clinical practice.
The potential advantage of providing vitamin A with 
surfactant is that babies would receive the antioxidant 
locally when the oxidant stress is potentially the greatest, as 
opposed to giving vitamin A intramuscularly (Tyson et al 
1999; Darlow and Graham 2002) later when the oxidant dam-
age has already caused structural damage to the pulmonary 
basement membrane within epithelial cells (D’Angio and 
Maniscalco 2004). The drawback to this approach is that it 
provides a limited dose of vitamin A to patients who would 
receive at the most between 1 to 3 intra-tracheal adminis-
trations of surfactant. For this reason we tested a 10-fold 
greater concentration of retinyl acetate (50,000 IU), which 
exhibited a surface tension comparable to the preparation 
with 5000 IU (15 ± 1 vs 13 ± 4 nN/m). In preliminaries, the 
bioavailability of retinyl acetate provided intratracheally with 
surfactant was documented in animals that showed increased 
hepatic levels of retinol (Bronstein et al 2005). It remains 
to be tested whether surfactant spiked with vitamin A will 
have a greater effect on pulmonary levels than intravenous 
supplementation (Lavoie et al 2007) and if this is associated 
with changes in lung function.
Providing vitamin A with surfactant as a lipophilic 
vehicle may be a less-invasive mode of delivery than by 
intramuscular injections in subjects requiring surfactant 
administration. Our ﬁ  ndings warrant further preclinical 
studies to test the biochemical, pharmacological, histologi-
cal and clinical responses to this noninvasive mode of co-
administration of vitamin A.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Allwood MC, Martin HJ. 2000. The photodegradation of vitamins A and E in 
parenteral nutrition mixtures during infusion. Clin Nutr, 19:339–42.
Ambalavan N, Wu TJ, Tyson JE, et al. 2003. A comparison of three vitamin 
A dosing regimens in extremely-low-birth-weight-infants. J Pediatr, 
142:656–61.
Ambalavanan N, Kennedy K, Tyson J, et al. 2004. Survey of vitamin 
A supplementation for extremely-low-birth-weight infants: is clinical 
practice consistent with the evidence? J Pediatr, 145:304–7.
Bernhard W, Mottaghian J, Gebert A, et al. 2000. Commercial versus native 
surfactants. Surface activity, molecular components, and the effect of 
calcium. Am J Respir Crit Care Med, 162:1524–33.
Biesalski HK, Reifen R, Furst RP, et al. 1999. Retinyl palmitate supplemen-
tation by inhalation of an aerosol improves vitamin A status of preschool 
children in Gondar (Ethiopia). Br J Nutr, 82:179–82.
Bronstein V, Khashu M, Singh A, et al. 2005. Exploring a novel mode of 
vitamin A supplementation: intratracheal administration with surfactant 
[abstract]. Pediatr Res, 57:2507.
Brooks AD, Tong W, Benedetti F, et al. 2000. Inhaled aerosolization of all-
trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother 
Pharmacol, 46:313–18.
D’Angio CT, Maniscalco WM. 2004. Bronchopulmonary dysplasia in 
preterm infants: pathophysiology and management strategies. Pediatric 
Drugs, 6:303–30.
Dahl AR, Grossi IM, Houchens DP, et al. 2000. Inhaled isotretinoin 
(13-cis retinoic acid) is an effective lung cancer chemopreventive 
agent in A/J mice at low doses: a pilot study. Clin Cancer Res, 
6:3015–24.
Darlow BA, Graham PJ. 2002. Vitamin A supplementation for preventing 
morbidity and mortality in very low birthweight infants. Cochrane 
Database Syst Rev, 4:CD000501.
Eggert LD, Rusho WJ, MacKay MW, et al. 1982. Calcium and phosphorus 
compatibility in parenteral nutrition solutions for neonates. Am J Hosp 
Pharm, 39:49–53.
Enhorning G. 1977. Pulsating bubble technique for evaluating pulmonary 
surfactant. J Appl Physiol, 43:198–203.
Enhorning G. 2001. Pulmonary surfactant function studied with the pulsat-
ing bubble surfactometer (PBS) and the capillary surfactometer (CS). 
Comp Biochem Biophysiol, 129:221–6.
Francisko A, Chakaraborty J, Yunus M, et al. 1993. Acute toxicity of vitamin 
A given with vaccine in infancy. Lancet, 342:526–7.
Haas C, Genzel-Boroviczeny O, Koletzko B. 2002. Losses of vitamin A and 
E in parenteral nutrition suitable for premature infants. Eur J Clin 
Nutr, 56:906–12.
Hustead VA, Gutcher GR, Anderson SA, et al. 1984. Relationship of vitamin 
A (retinol) status to lung disease in the preterm infant. J Pediatr, 
105:610–15.
Kohlhauﬂ   M, Haussinger K, Stanzel F, et al. 2002. Inhalation of aerosol-
ized vitamin A: reversibility of metaplasia and dysplasia of human 
respiratory epithelia-a prospective pilot study. Eur J Med Res, 
7:72–8.
Lavoie JC, Chessex P, Rouleau T, et al. 2007. Shielding parenteral multi-
vitamins from light increases vitramin A and E concentration in lung 
of newborn guinea pigs. Clinical Nutr, 26:341–7.
Maden M, Hind M. 2004. Retionoic acid in alveolar development, mainte-
nance and regeneration. Phil Trans R Soc Lond, B359:799–808.Drug Design, Development and Therapy 2008:2 150
Bronshtein et al
McMillan D, Chernick V, Finer N, et al. 1995. Effects of two rescue doses 
of synthetic surfactant in 344 infants with respiratory distress syndrome 
weighing 750 to 1249 grams: a double-blind, placebo-controlled 
multicenter Canadian trial. Canadian Exosurf Neonatal Study Group. 
J Pediatr, 126:S90–8.
Ozer EA, Kumral A, Ozer E, et al. 2005. Effect of retinoic acid on oxygen 
induced lung injury in the newborn rat. Pediatr Pulmonol, 39:35–40.
Shenai JP, Chytil F, Stahlman MT. 1985. Vitamin A status of neonates with 
bronchopulmonary dysplasia. Pediatr Res, 19:185–8.
Smith VC, Zupancic JA, MvCormick MC, et al. 2004. Rehospitalisation in 
the ﬁ  rst year of life among infants with bronchopulmonary dysplasia. 
J Pediatr, 144:799–803.
Snyder JM, Jenkins-Moore M, Jackson SK, et al. 2005. Alveolarization in 
retinoic acid receptor-beta-deﬁ  cient mice. Pediatr Res, 57:384–91.
Stenmark KR, Abman SH. 2005. Lung vascular development: implication 
for the pathogenesis of bronchopulmonary dysplasia. Ann Rev Physiol, 
67:623–61.
Tyson JE, Wright LL, Oh W, et al. 1999. Vitamin A supplementation for 
extremely-low-birthweight infants: National Institute of Child Health 
and Human Development Neonatal Research Network. N Engl J Med, 
340:1962–8.
Wardle SP, Hughes A, Chen S, et al. 2001. Randomized controlled trial of 
oral vitamin A supplementation in preterm infants to prevent chronic 
lung diseases. Arch Dis Child Fetl Neonatal Ed, 84:F10–13.
Wong JC, McDougal AR, Tofan M, et al. 2006. Doubling calcium 
and phosphate concentrations in neonatal parenteral nutrition 
solutions using monobasic potassium phosphate. J Am Coll Nutr, 
25:70–7.